Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

CG Oncology's bladder cancer treatment beats expectations in Phase 3

EndpointsView source article

Part of story

CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3

CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.

Nov 16, 2026·3 sourcesCancer immunotherapyCancer & OncologyCancer treatment breakthroughsClinical trialsOncolytic virotherapy
CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3
00

Other sources for this story

Reuters

CG Oncology's immunotherapy reduces risk of tumor recurrence in bladder cancer trial | Reuters

STAT News

Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence